1
|
Xiao X, Zheng H, Xiong M, Chen X, Jiang L, Hu Y. Genotypic and phenotypic characteristics of ADGRV1 mutations in four children and functional validation in a zebrafish model. Gene 2025; 942:149246. [PMID: 39826705 DOI: 10.1016/j.gene.2025.149246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2024] [Revised: 01/09/2025] [Accepted: 01/10/2025] [Indexed: 01/22/2025]
Abstract
Mutations in ADGRV1 can cause seizures, but the mechanism remains unclear. The zebrafish model can be used to assess the functions of human ADGRV1 and its variant alleles during embryonic development. In this study, we summarized the phenotypic and genotypic characteristics of four children with ADGRV1 variation and based on this, we validated the ADGRV1 loss phenotype in an adgrv1-knockout zebrafish model. We retrospectively analyzed the clinical and genotypic characteristics of four pediatric patients diagnosed as having ADGRV1 mutations at Children's Hospital Affiliated to Chongqing Medical University from April 2019 to February 2022. Moreover, we used the adgrv1-knockout zebrafish larvae model and performed morphological, behavioral, and neuroelectrophysiological testing. We found that of the four included children, two had epilepsy, one had paroxysmal kinesigenic dyskinesia, and one had febrile seizure plus. Three children had a history of febrile seizures, whereas two had a family history of febrile seizures. Three children had well-controlled clinical epilepsy seizures or motor disorders. Finally, one child with spontaneous mutation had epigenetic abnormalities and comprehensive developmental delay, one had language developmental delay, and two (paternal or maternal) had a good prognosis. Regarding the zebrafish model, the cas9-control and adgrv1-edited groups demonstrated significant differences in the interocular areas of the zebrafish observed in the open field and the maximum swimming velocity under light stimulus. In neuroelectrophysiological testing, epilepsy-related signals were observed in 2 of 26 adgrv1-edited group fish. We believe that, mutations in the ADGRV1 may lead to epileptic seizures and movement disorders. The patients usually have a history of febrile seizures or a family history. Through research using the zebrafish model, it has been found that ADGRV1 mutations can affect the expression of eye and the neuromotor development of zebrafish larvae. This might be one of the reasons for epileptic seizures caused by ADGRV1 gene mutations.
Collapse
Affiliation(s)
- Xiao Xiao
- Department of Neurology Children's Hospital of Chongqing Medical University, China; National Clinical Research Center for Child Health and Disorders, China; Ministry of Education Key Laboratory of Child Development and Disorders, China; Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, China
| | - Hao Zheng
- Department of Neurology Children's Hospital of Chongqing Medical University, China; National Clinical Research Center for Child Health and Disorders, China; Ministry of Education Key Laboratory of Child Development and Disorders, China; Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, China
| | - Miao Xiong
- Department of Neurology Children's Hospital of Chongqing Medical University, China; National Clinical Research Center for Child Health and Disorders, China; Ministry of Education Key Laboratory of Child Development and Disorders, China; Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, China
| | - Xiaoqi Chen
- Department of Neurology Children's Hospital of Chongqing Medical University, China; National Clinical Research Center for Child Health and Disorders, China; Ministry of Education Key Laboratory of Child Development and Disorders, China; Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, China
| | - Li Jiang
- Department of Neurology Children's Hospital of Chongqing Medical University, China; National Clinical Research Center for Child Health and Disorders, China; Ministry of Education Key Laboratory of Child Development and Disorders, China; Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, China
| | - Yue Hu
- Department of Neurology Children's Hospital of Chongqing Medical University, China; National Clinical Research Center for Child Health and Disorders, China; Ministry of Education Key Laboratory of Child Development and Disorders, China; Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, China.
| |
Collapse
|
2
|
An W, Tian Q, Guo P, Chen M, Zhang T, Yang P, Zhang S. Danggui Buxue Decoction and its components dilate coronary artery through activating the inward rectification K + channels pathway. JOURNAL OF ETHNOPHARMACOLOGY 2025; 338:119064. [PMID: 39521101 DOI: 10.1016/j.jep.2024.119064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/09/2024] [Revised: 11/03/2024] [Accepted: 11/06/2024] [Indexed: 11/16/2024]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Danggui Buxue Decoction (DBD), a classic representative prescription of invigorating Qi and producing blood, is used to treat coronary heart disease angina pectoris and vascular injury diseases. Abnormal coronary artery is an important cause of cardiovascular disease. However, the mechanism of DBD dilates coronary arteries is still unclear. AIM OF THE STUDY This study aimed to elucidate the impacts and distinctions among DBD, Astragalus, Angelica sinensis, and identified active components on pre-constricted coronary arteries, as well as to delve deeper into their respective mechanisms. MATERIALS AND METHODS After the preconstriction of a rat isolated coronary artery ring with either 30 mM KCl or 200 nM U46619, the vascular tension was observed following the addition of DBD, and other components. Subsequently, the impact of these active components on coronary blood flow (CBF) was confirmed through in vivo testing. Further investigation into the underlying mechanism was carried out using a combination of blockers, molecular docking, surface plasmon resonance (SPR), cell heat transfer analysis (CETSA), and patch-clamp techniques. RESULTS In vitro experiments showed that DBD and its components butylidenephthalide, ligustilide, calycosin, and quercetin could dilate coronary artery preconstricted with either 30 mM KCl or 200 nM U46619. In addition, the active ingredient was found to significantly increase CBF. Mechanistically, BaCl2 was found to reduce the relaxation effect of the drug by adding a blocker. Molecular docking, SPR and CETSA results showed that the active ingredients had a strong binding potential with inward rectification K+ channels (KIR) channel protein. Patch clamp studies demonstrate that quercetin can increase KIR current, and BaCl2 can significantly reduce its current. CONCLUSIONS The active components of DBD, butylidenephthalide, ligustilide, calycosin, and quercetin, activate KIR channels to relax coronary artery and increase CBF.
Collapse
Affiliation(s)
- Wenqiao An
- Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611100, China; School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 611100, China
| | - Qianqian Tian
- Faculty of Social Sciences, The University of Hong Kong, 999077, China
| | - Pengmei Guo
- Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611100, China
| | - Mingzhu Chen
- School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 611100, China
| | - Ting Zhang
- Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611100, China
| | - Peng Yang
- Chengdu Fifth People's Hospital, Chengdu, 611100, China.
| | - Sanyin Zhang
- Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611100, China.
| |
Collapse
|
3
|
Imamura T, Makiyama T, Ozawa J, Sonoda K, Kato K, Aizawa T, Kashiwa A, Gao J, Huang H, Yamamoto Y, Kohjitani H, Aoki H, Watanabe S, Muraji S, Kojima T, Yoshinaga M, Ohno S, Suzuki H, Sumitomo N, Nakagawa Y, Ono K, Horie M, Kimura T. Sex-specific clinical course of young patients with Brugada syndrome. Eur Heart J 2025:ehae739. [PMID: 39908976 DOI: 10.1093/eurheartj/ehae739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2024] [Revised: 09/28/2024] [Accepted: 10/10/2024] [Indexed: 02/07/2025] Open
Affiliation(s)
- Tomohiko Imamura
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
- Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Hidaka, Japan
- Department of Preventive Services, Kyoto University School of Public Health, Kyoto, Japan
| | - Takeru Makiyama
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
- Department of Community Medicine Supporting System, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Junichi Ozawa
- Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Keiko Sonoda
- Medical Genome Center, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Koichi Kato
- Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan
| | - Takanori Aizawa
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
- Research Unit on Cardiovascular and Metabolic Diseases, Sorbonne Université, Paris, France
| | - Asami Kashiwa
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
- Department of Cardiology, Niigata City Hospital, Niigata, Japan
| | - Jingshan Gao
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
- Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA
| | - Hai Huang
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Yuta Yamamoto
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
- Department of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | - Hirohiko Kohjitani
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
- Department of Biomedical Data Intelligence, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Hisaaki Aoki
- Department of Pediatric Cardiology, Osaka Women's and Children's Hospital, Izumi, Japan
| | - Seiichi Watanabe
- Department of Pediatrics, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan
| | - Shota Muraji
- Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Hidaka, Japan
| | - Takuro Kojima
- Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Hidaka, Japan
| | - Masao Yoshinaga
- Department of Pediatrics, Kagoshima Medical Center, Kagoshima, Japan
| | - Seiko Ohno
- Medical Genome Center, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Hiroshi Suzuki
- Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - Naokata Sumitomo
- Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Hidaka, Japan
| | - Yoshihisa Nakagawa
- Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Minoru Horie
- Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan
| | - Takeshi Kimura
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
- Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan
| |
Collapse
|
4
|
Drazner MH, Bozkurt B, Cooper LT, Aggarwal NR, Basso C, Bhave NM, Caforio ALP, Ferreira VM, Heidecker B, Kontorovich AR, Martín P, Roth GA, Van Eyk JE. 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2025; 85:391-431. [PMID: 39665703 DOI: 10.1016/j.jacc.2024.10.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2024]
|
5
|
van Deventer BS, du Toit-Prinsloo L, van Niekerk C. Next generation sequencing: a possible answer to sudden unexplained deaths in a young South African cohort? Forensic Sci Med Pathol 2025:10.1007/s12024-025-00944-6. [PMID: 39900885 DOI: 10.1007/s12024-025-00944-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/07/2025] [Indexed: 02/05/2025]
Abstract
Sudden cardiac death (SCD) is a major public health concern. In sub-Saharan Africa (SSA), including South Africa, there is a lack of reliable statistics on the incidence of SCD, even though there has been a fourfold increase in noncommunicable diseases (NCD), particularly cardiovascular diseases (CVD). Sudden cardiac death contributes to an estimated 50% of all cardiovascular deaths, which highlights South Africa's need for research into better detection, treatment and prevention. This study aimed to identify an inherited cardiac arrhythmogenic disorder, linked to variants in cardiomyopathy- and arrhythmia-related genes, as a potential contributing factor to sudden cardiac deaths. DNA was extracted from blood samples collected at autopsy of 51 sudden unexpected death (SUD) cases, and subjected to next-generation sequencing (NGS) of 49 genes linked to inherited cardiac arrhythmogenic disorders. Variants were annotated and interpretated for clinical significance using the Galaxy bioinformatic platform. In total, 175 different missense variants were identified in the study population (n = 51). Of these, 92.5% (162/175) were known, documented variants, and the remaining 7.4% (13/175) were considered novel. Of the known variants, 78.4% (127/162) were of benign/likely benign significance, 20.4% (33/162) were variants of unknown significance (VUS), and 1.2% (2/162) was pathogenic. The 13 novel variants were analysed using online prediction software, with 92.3% (12/13) predicted to be likely benign and 7.7% (1/13) grouped into the VUS category. Post-mortem genetic testing provided evidence of a genetic arrhythmic/cardiac conduction disorder as the probable pathogenic basis for approximately 4% (2/51) of sudden unexpected death (SUD) cases.
Collapse
Affiliation(s)
- Barbara Stroh van Deventer
- Department of Forensic Medicine, University of Pretoria, R4-41 Pathology Building Prinshof Campus, Pretoria, 0002, South Africa.
- Department of Chemical Pathology, National Health Laboratory Services, Pretoria, Australia.
| | - Lorraine du Toit-Prinsloo
- New South Wales Health Pathology, Forensic and Analytical Science Service (FASS), New Castle, New South Wales, Australia
| | - Chantal van Niekerk
- Department of Chemical Pathology, Faculty of Health Sciences, University of Pretoria / NHLS, Pretoria, South Africa
| |
Collapse
|
6
|
Yaylacioglu Tuncay F, Reeves MJ, Yousaf S, Ullah E, Guan B, Goetz KE, Tumminia SJ, Hufnagel RB. Genotype-Phenotype Spectrum of eyeGENE Patients With Familial Exudative Vitreoretinopathy: Novel Variants in Norrin/β-Catenin Signaling Pathway Genes. Invest Ophthalmol Vis Sci 2025; 66:9. [PMID: 39903177 DOI: 10.1167/iovs.66.2.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2025] Open
Abstract
Purpose To report the variants and genotype-phenotype correlations in patients with familial exudative vitreoretinopathy (FEVR) included in the eyeGENE database. Methods A retrospective study was conducted in a cohort of 122 eyeGENE patients from 114 families with FEVR. Clinical details and genetic test results were provided by referring clinicians and clinical laboratories in the eyeGENE network, respectively. Genotype and phenotype information was reviewed, and reported variants were reclassified. Results Genetic test reports of 50 probands revealed 52 variants in the four genes of the Norrin/β-catenin signaling pathway: LRP5, FZD4, TSPAN12, and NDP. Following variant reclassification, 35 of the reported variants were interpreted as pathogenic or likely pathogenic (12 in LRP5, 11 in FZD4, seven in TSPAN12 and five in NDP), providing a conclusive test result for nearly one-third (32%) of the probands. Among the reported variants, 18 were novel (34.6%) and two-thirds were missense. Retinal detachment was reported less in patients with variants in TSPAN12 (P = 0.017). One-third of the patients (33.3%) with an FZD4 variant had asymmetric findings. In contrast, asymmetry was less pronounced in patients with variants in TSPAN12 (11.1%). Conclusions This was one of the largest cohorts reviewed from North America, expanding the variant spectrum in FEVR. Among the eyeGENE FEVR patients, disease-associated variants in Norrin/β-catenin signaling pathway genes can explain one-third of the cohort. LRP5 and FZD4 variants were the most common. The genotype-phenotype correlations supported the phenotypic variability in FEVR.
Collapse
Affiliation(s)
- Fulya Yaylacioglu Tuncay
- Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States
- Medical Biology Department, Gulhane Medical Faculty, University of Health Sciences, Ankara, Turkey
| | - Melissa J Reeves
- Office of Data Science and Health Informatics, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States
| | - Sairah Yousaf
- Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States
| | - Ehsan Ullah
- Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States
| | - Bin Guan
- Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States
| | - Kerry E Goetz
- Office of Data Science and Health Informatics, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States
| | - Santa J Tumminia
- Office of the Director, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States
| | - Robert B Hufnagel
- Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States
- Center for Integrated Healthcare Research, Kaiser Permanente Hawaii Region, Honolulu, Hawaii, United States
| |
Collapse
|
7
|
Alsaloum M, Dib-Hajj SD, Page DA, Ruben PC, Krainer AR, Waxman SG. Voltage-gated sodium channels in excitable cells as drug targets. Nat Rev Drug Discov 2025:10.1038/s41573-024-01108-x. [PMID: 39901031 DOI: 10.1038/s41573-024-01108-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/21/2024] [Indexed: 02/05/2025]
Abstract
Excitable cells - including neurons, muscle cells and cardiac myocytes - are unique in expressing high densities of voltage-gated sodium (NaV) channels. This molecular adaptation enables these cells to produce action potentials, and is essential to their function. With the advent of the molecular revolution, the concept of 'the' sodium channel has been supplanted by understanding that excitable cells in mammals can express any of nine different forms of sodium channels (NaV1.1-NaV1.9). Selective expression in particular types of cells, together with a key role in controlling action potential firing, makes some of these NaV subtypes especially attractive molecular targets for drug development. Although these different channel subtypes display a common overall structure, differences in their amino acid sequences have provided a basis for the development of subtype-specific drugs. This approach has resulted in exciting progress in the development of drugs for epilepsy, cardiac disorders and pain. In this Review, we discuss recent progress in the development of drugs that selectively target each of the sodium channel subtypes.
Collapse
Affiliation(s)
- Matthew Alsaloum
- Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
| | | | - Dana A Page
- Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Peter C Ruben
- Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada
| | | | - Stephen G Waxman
- Department of Neurology, Yale School of Medicine, New Haven, CT, USA.
| |
Collapse
|
8
|
Calvelli P, Cerrato N, Giustetto C, Saglietto A, Anselmino M, Curcio A. Which Brugada patient deserves continuous ECG monitoring through implantable loop recorder? An evidence update. J Cardiovasc Med (Hagerstown) 2025; 26:64-71. [PMID: 39841911 DOI: 10.2459/jcm.0000000000001696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2024] [Accepted: 12/05/2024] [Indexed: 01/24/2025]
Abstract
Brugada syndrome (BrS) is a genetic condition that increases the risk of life-threatening arrhythmias, which can result in sudden cardiac death (SCD). Implantable loop recorders (ILRs) have become a key tool in managing patients with unexplained syncope, and guidelines advise their use in individuals with recurrent, unexplained syncope or palpitations. However, the role of ILRs in inherited arrhythmic conditions like BrS remains a topic of debate. Most patients newly diagnosed with BrS show no symptoms, but around 30% may experience symptoms such as syncope or palpitations, which can arise from arrhythmic issues or other causes like neurally mediated reflexes. Accurately assessing the cause of these symptoms is crucial to evaluate the risk of SCD. This document aims to examine current evidence on the role of ILR implantation in patients with BrS. The most frequent arrhythmias recorded by ILR are supraventricular arrhythmias and conduction disorders; ventricular arrhythmias, usually nonsustained, are rarely recorded. Symptoms-to-rhythm correlation by ILR can have therapeutic implications in case of recorded arrhythmias (initiation of drug therapy, ablation procedures or defibrillator/pace-maker implantation), provide reassurance in patients without rhythm disorders documented and improve their quality of life. However, given the low rate of detected arrhythmias, the clinical value of ILR in asymptomatic patients needs further evaluation.
Collapse
Affiliation(s)
- Pierangelo Calvelli
- Division of Cardiology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende (CS)
| | | | - Carla Giustetto
- Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza di Torino Hospital and Department of Medical Sciences, University of Turin, Italy
| | - Andrea Saglietto
- Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza di Torino Hospital and Department of Medical Sciences, University of Turin, Italy
| | - Matteo Anselmino
- Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza di Torino Hospital and Department of Medical Sciences, University of Turin, Italy
| | - Antonio Curcio
- Division of Cardiology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende (CS)
| |
Collapse
|
9
|
Wattanachayakul P, Srikulmontri T, Prasitsumrit V, Suenghataiphorn T, Danpanichkul P, Kewcharoen J, Charoenngam N, Mainigi S. Malnutrition and risks of atrial fibrillation recurrence after catheter ablation. J Arrhythm 2025; 41:e13196. [PMID: 39817025 PMCID: PMC11730718 DOI: 10.1002/joa3.13196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2024] [Revised: 10/27/2024] [Accepted: 11/21/2024] [Indexed: 01/18/2025] Open
Abstract
Background Recent data showed an association between malnutrition and increased all-cause mortality and thromboembolic risk in patients with atrial fibrillation (AF). However, the impact of malnutrition on the clinical outcomes for patients undergoing catheter ablation for AF is still debated. Our study aimed to examine this relationship using all existing available data. Methods We conducted a systematic review of MEDLINE and EMBASE databases from inception to April 2024, analyzing the association between malnutrition, assessed by the Geriatric Nutritional Risk Index (GNRI), and the risk of AF recurrence in patients who underwent catheter ablation for AF, compared to those without malnutrition. Relative Risk (RR) or hazard ratio (HR) and 95% CIs were retrieved from each study and combined using the generic inverse variance method. Results We included 3 cohort studies with 1697 participants undergoing AF ablation (10.9%) who had malnutrition indicated by GNRI score below 98. Patients with malnutrition had a higher risk of AF recurrence following catheter ablation for AF compared to those without malnutrition (Pooled RR = 2.74, 95% CI 1.36-5.51, I 2 = 67%, p = .005). Conclusions Our pooled analysis indicates that malnourished patients undergoing catheter ablation for AF have an increased risk of AF recurrence compared to non-malnourished patients.
Collapse
Affiliation(s)
- Phuuwadith Wattanachayakul
- Department of MedicineJefferson Einstein HospitalPhiladelphiaPennsylvaniaUSA
- Sidney Kimmel Medical CollegeThomas Jefferson UniversityPhiladelphiaPennsylvaniaUSA
| | - Thitiphan Srikulmontri
- Department of MedicineJefferson Einstein HospitalPhiladelphiaPennsylvaniaUSA
- Sidney Kimmel Medical CollegeThomas Jefferson UniversityPhiladelphiaPennsylvaniaUSA
| | - Vitchapong Prasitsumrit
- Department of Medicine, Faculty of Medicine Siriraj HospitalMahidol UniversityBangkokThailand
| | | | | | - Jakrin Kewcharoen
- Division of CardiologyUniversity of California san FranciscoSan FranciscoCaliforniaUSA
| | - Nipith Charoenngam
- Endocrine UnitMassachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Sumeet Mainigi
- Sidney Kimmel Medical CollegeThomas Jefferson UniversityPhiladelphiaPennsylvaniaUSA
- Division of Cardiovascular DiseaseJefferson Einstein HospitalPhiladelphiaPennsylvaniaUSA
| |
Collapse
|
10
|
Thierry IP, Muller SA, Baas AF, Dooijes D, van Loon RLE, Schoemaker AE, van der Harst P, Oerlemans MIFJ, Baars HF, Hassink RJ, Asselbergs FW, van Tintelen JP, Te Riele ASJM. Yield of family screening for dilated cardiomyopathy: 10-year experience at a multidisciplinary cardiogenetic outpatient clinic. Neth Heart J 2025; 33:46-54. [PMID: 39833651 PMCID: PMC11757811 DOI: 10.1007/s12471-024-01924-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/02/2024] [Indexed: 01/22/2025] Open
Abstract
INTRODUCTION Current family screening approaches in dilated cardiomyopathy (DCM) depend on the presence or absence of a familial genetic variant, in which variant pathogenicity (i.e. benign or pathogenic) classification drives screening recommendations. However, this approach has never been systematically evaluated. METHODS To describe the yield of DCM family screening stratified by variant classification in the Netherlands, we included 358 relatives (mean age ± standard deviation: 44.4 ± 15.9 years at baseline; 52% female; 41% (likely) pathogenic (LP/P) variant carriers from 210 families). Demographics, symptoms and genetic/cardiac test results were obtained. Endpoints were the development of DCM (left ventricular ejection fraction < 50% of non-ischaemic aetiology) or occurrence of major adverse cardiovascular events (MACE) (i.e. heart failure hospitalisation, ventricular arrhythmia or death). Probability of DCM or MACE was assessed with the Kaplan-Meier method. RESULTS DCM was present in 32 relatives (9%) (25/32 (78%) with LP/P variant) at baseline and in an additional 10/97 relatives (10%) (9/10 (90%) with LP/P variant) who were re-evaluated during a median follow-up time of 5.0 years (interquartile range: 3.2-7.4). Of the 128 relatives without the familial LP/P variant, none developed DCM. MACE was experienced by 5 relatives (1%) (4/5 (80%) with LP/P variant), all of whom had DCM at the time of the event. CONCLUSION The yield of DCM family screening was ~10% at baseline and another ~10% during 5‑year follow-up. Relatives without the familial LP/P variant could be safely discharged. These results reinforce the use of a genetics-first screening approach in relatives from families with an LP/P variant. This will lower the burden on resources in Dutch hospitals and help allocate resources to those who are most likely to benefit.
Collapse
Affiliation(s)
- Isabelle P Thierry
- Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Steven A Muller
- Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands
- Netherlands Heart Institute, Utrecht, The Netherlands
- Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands
| | - Annette F Baas
- Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands
- Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Dennis Dooijes
- Netherlands Heart Institute, Utrecht, The Netherlands
- Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
| | - R Laura E van Loon
- Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands
- Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Angela E Schoemaker
- Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands
- Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Pim van der Harst
- Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands
- Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands
| | - Marish I F J Oerlemans
- Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands
- Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands
| | | | - Rutger J Hassink
- Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands
- Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands
| | - Folkert W Asselbergs
- Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands
- Institute of Cardiovascular Science, Faculty Netherlands Health Sciences, University College London, London, UK
- Department of Cardiology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands
- Health Data Research UK and Institute of Health Informatics, University College London, London, UK
| | - J Peter van Tintelen
- Netherlands Heart Institute, Utrecht, The Netherlands
- Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands
- Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Anneline S J M Te Riele
- Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Netherlands Heart Institute, Utrecht, The Netherlands.
- Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands.
| |
Collapse
|
11
|
Protonotarios A, Asimaki A, Basso C, Xylouri Z, Monda E, Protonotarios I, Crisci G, Abrahms DJR, Anastasakis A, Antoniades L, Bakalakos A, Carbone A, S. Coonar A, Gimeno JR, Lazaros G, Lerakis S, Mestroni L, Papadopoulos G, Pecchia L, Prandi FR, Syrris P, Cadrin-Turigny J, Vasilakis A, Saffitz JE, Gaetano Thiene S, Elliott PM, Kaski JP, McKenna WJ, Bossone E, Limongelli G, Tsatsopoulou A. Naxos Disease and Related Cardio-Cutaneous Syndromes. JACC. ADVANCES 2025; 4:101547. [PMID: 39877668 PMCID: PMC11773020 DOI: 10.1016/j.jacadv.2024.101547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/19/2024] [Revised: 11/19/2024] [Accepted: 12/01/2024] [Indexed: 01/31/2025]
Abstract
Naxos disease is a rare autosomal recessive condition combining arrhythmogenic right ventricular cardiomyopathy, woolly hair, and palmoplantar keratoderma. The first identified causative variant was in the gene encoding the desmosomal protein plakoglobin. Naxos disease exhibits fibro-fatty myocardial replacement with immunohistological abnormalities in cardiac protein and signaling pathways, highlighting the role of inflammation and potential anti-inflammatory treatments. Childhood cutaneous signs precede cardiac features, which are diagnosed by familial and genetic evaluation, electrocardiography and cardiac imaging. Disease progression necessitates holistic care with risk management and lifestyle adjustments, often needing treatment for arrhythmia and heart failure. Similar phenotypes have been linked to desmoplakin and rarely desmocollin2 gene variants, highlighting the importance of familial and genetic evaluation. This document summarizes current knowledge on Naxos disease and related cardiocutaneous syndromes and initiates an international endeavor to collect and study all global cases, aiming to improve understanding, treatment, and patient care through shared data and research.
Collapse
Affiliation(s)
| | - Angeliki Asimaki
- Cardiovascular and Genomics Research Institute of City, St George’s University of London, London, UK
| | | | | | - Emanuele Monda
- Department of Traslational Sciences, University of Campania ‘Luigi Vanvitelli’, Naples, Italy
| | - Ioannis Protonotarios
- Cardiovascular and Genomics Research Institute of City, St George’s University of London, London, UK
| | - Giulia Crisci
- University of Naples Federico II, Naples, Italy
- Department of Cardiology, San Paolo Hospital, University of Milan, Milan, Italy
| | - Dominic JR. Abrahms
- Center for Cardiovascular Genetics, Boston Children’s Hospital, Harvard Medical School, Boston, USA
| | - Aris Anastasakis
- Inherited Cardiovascular Diseases, Onassis Cardiac Surgery Centre, Athens, Greece
| | | | - Athanasios Bakalakos
- Centre for Heart Muscle Disease, UCL Institute of Cardiovascular Science, London, UK
| | | | - Aman S. Coonar
- Cardiothoracic Surgery, Royal Papworth Hospital, Cambridge University Health Partners, Cambridge, UK
| | - Juan Ramon Gimeno
- Inherited Cardiac Disease Department (CSUR/ ERN Guard Heart), Virgen de la Arrixaca University Hospital, Murcia, Spain
| | - George Lazaros
- George Lazaros, First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Stamatis Lerakis
- Department of Cardiology, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY
| | - Luisa Mestroni
- Medicine/Cardiology, Genetics Program, University of Colorado Cardiovascular Institute, Aurora, USA
| | | | | | | | - Petros Syrris
- Centre for Heart Muscle Disease, UCL Institute of Cardiovascular Science, London, UK
| | - Julia Cadrin-Turigny
- Cardiovascular Genetics Center, Montréal Heart Institute, Faculty of Medicine, University of Montréal, Montréal, Québec, Canada
| | | | - Jeffrey E. Saffitz
- Harvard Medical School, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, USA
| | | | - Perry M. Elliott
- Centre for Heart Muscle Disease, UCL Institute of Cardiovascular Science, London, UK
| | - Juan Pablo Kaski
- Centre for Heart Muscle Disease, UCL Institute of Cardiovascular Science, London, UK
| | - William J. McKenna
- Centre for Heart Muscle Disease, UCL Institute of Cardiovascular Science, London, UK
| | | | - Giuseppe Limongelli
- Department of Traslational Sciences, University of Campania ‘Luigi Vanvitelli’, Naples, Italy
| | - Adalena Tsatsopoulou
- Precision Medicine Network in Cardiology Onassis Cardiac Surgery Center, Athens, Greece
- Pediatric Clinic, Naxos, Cyclades, Greece
| |
Collapse
|
12
|
Liu Y, Chen X, Tan X, Huang Y, Zhang W, Wang Z, Yang L, Wang Y, Li Z, Zhang X. Double network hydrogels encapsulating genetically modified dedifferentiated chondrocytes for auricular cartilage regeneration. J Mater Chem B 2025; 13:1823-1844. [PMID: 39745373 DOI: 10.1039/d4tb02352h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2025]
Abstract
Microtia profoundly affects patients' appearance and psychological well-being. Tissue engineering ear cartilage scaffolds have emerged as the most promising solution for ear reconstruction. However, constructing tissue engineering ear cartilage scaffolds requires multiple passaging of chondrocytes, resulting in their dedifferentiation and loss of their special phenotypes and functions. To tackle these issues, here we employ guanidinobenzoic acid (GBA) modified generation 5 polyamidoamine (PAMAM) dendrimers (PG) as a Runx1 plasmid carrier to construct PG/pRunx1 polyplex nanoparticles. The PG/pRunx1 polyplexes are transfected into human auricular chondrocytes, significantly mitigating chondrocyte dedifferentiation and enhancing cartilage regeneration during the in vitro culture. Furthermore, we develop highly porous double-network hydrogels based on methacrylate-functionalized and oxidized chondroitin sulfate and carbohydrazide-modified gelatin and the hydrogels possessed both dynamic adaptability and mechanical support characteristics by reversible dynamic covalent crosslinking and static covalent crosslinking, serving as an ideal scaffold for tissue engineering. Consequently, chondrocytes treated with PG/pRunx1 polyplex nanoparticles are incorporated into the hydrogels to construct tissue-engineered auricular cartilage scaffolds. After subcutaneous implantation in nude mice, the scaffolds containing chondrocytes treated with PG/pRunx1 nanoparticles showed more mature cartilaginous tissue, characterized by prominent ECM deposition and enhanced chondrogenesis. Therefore, this research provides a novel strategy for the development of tissue-engineered auricular cartilage scaffolds.
Collapse
Affiliation(s)
- Yang Liu
- Department of Plastic and Burn Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
| | - Xiaoting Chen
- Animal Experimental Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Xueqin Tan
- Department of Plastic and Burn Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
| | - Yeqian Huang
- Department of Plastic and Burn Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
| | - Wen Zhang
- National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.
| | - Zhicun Wang
- National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.
| | - Li Yang
- National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.
| | - Yunbing Wang
- National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.
| | - Zhengyong Li
- Department of Plastic and Burn Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
| | - Xingdong Zhang
- National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.
| |
Collapse
|
13
|
Boemer F, Hovhannesyan K, Piazzon F, Minner F, Mni M, Jacquemin V, Mashhadizadeh D, Benmhammed N, Bours V, Jacquinet A, Harvengt J, Bulk S, Dideberg V, Helou L, Palmeira L, Dangouloff T, Servais L. Population-based, first-tier genomic newborn screening in the maternity ward. Nat Med 2025:10.1038/s41591-024-03465-x. [PMID: 39875687 DOI: 10.1038/s41591-024-03465-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2024] [Accepted: 12/12/2024] [Indexed: 01/30/2025]
Abstract
The rapid development of therapies for severe and rare genetic conditions underlines the need to incorporate first-tier genetic testing into newborn screening (NBS) programs. A workflow was developed to screen newborns for 165 treatable pediatric disorders by deep sequencing of regions of interest in 405 genes. The prospective observational BabyDetect pilot project was launched in September 2022 in a maternity ward of a public hospital in the Liege area, Belgium. In this ongoing observational study, 4,260 families have been informed of the project, and 3,847 consented to participate. To date, 71 disease cases have been identified, 30 of which were not detected by conventional NBS. Glucose-6-phosphate dehydrogenase deficiency was the most frequent disorder detected, with 44 positive individuals. Of the remaining 27 cases, 17 were recessive disorders. We also identified one false-positive case in a newborn in whom two variants in the AGXT gene were identified, which were subsequently shown to be located on the maternal allele. Nine heterozygous variants were identified in genes associated with dominant conditions. Results from the BabyDetect project demonstrate the importance of integrating biochemical and genomic methods in NBS programs. Challenges must be addressed in variant interpretation within a presymptomatic population and in result reporting and diagnostic confirmation.
Collapse
Affiliation(s)
- François Boemer
- Biochemical Genetics Lab, Department of Human Genetics, CHU Liege, University of Liege, Liege, Belgium.
| | | | - Flavia Piazzon
- Human Genetics Laboratory, GIGA-R Institute, University of Liege, Liege, Belgium
| | - Frédéric Minner
- Human Genetics Laboratory, GIGA-R Institute, University of Liege, Liege, Belgium
| | - Myriam Mni
- Human Genetics Laboratory, GIGA-R Institute, University of Liege, Liege, Belgium
| | - Valérie Jacquemin
- Human Genetics Laboratory, GIGA-R Institute, University of Liege, Liege, Belgium
| | | | - Noor Benmhammed
- Division of Child Neurology, Reference Center for Neuromuscular Diseases, Department of Pediatrics, CHU Liege, University of Liege, Liege, Belgium
| | - Vincent Bours
- Department of Human Genetics, CHU Liege, University of Liege, Liege, Belgium
| | - Adeline Jacquinet
- Department of Human Genetics, CHU Liege, University of Liege, Liege, Belgium
| | - Julie Harvengt
- Department of Human Genetics, CHU Liege, University of Liege, Liege, Belgium
| | - Saskia Bulk
- Department of Human Genetics, CHU Liege, University of Liege, Liege, Belgium
| | - Vinciane Dideberg
- Department of Human Genetics, CHU Liege, University of Liege, Liege, Belgium
| | - Laura Helou
- Bioinformatics Unit, Department of Human Genetics, CHU Liege, University of Liege, Liege, Belgium
- <
|
|